More Impact AG Secures US Patent for Needle-Free Speedinject Technology
Key Insights
More Impact AG (search) has been granted a US patent for Speedinject (search), an innovative needle-free injection technology developed by its subsidiary The Key Unternehmensberatung GmbH (search).
The electromagnetically driven system offers a precise, painless, and environmentally friendly alternative for drug administration, particularly targeting diabetes (search) and weight loss treatments.
With the US pharmaceutical market valued at $634 billion and projected to reach $884 billion in five years, Speedinject (search) is positioned to launch in both EU and US markets by late 2025.
More Impact AG (search) has secured a United States patent for its innovative Speedinject (search) technology, a needle-free injection system developed by its subsidiary The Key Unternehmensberatung GmbH (search). This patent approval represents a significant milestone in the company's international expansion strategy, particularly targeting the lucrative US pharmaceutical market.
The Frankfurt-based high-tech medical hub announced the patent on May 20, 2025, highlighting Speedinject (search)'s potential to transform drug administration for conditions like diabetes (search) and obesity (search). The technology eliminates traditional needles through an electromagnetically driven system for intramuscular injections, offering patients a more comfortable alternative.
Revolutionary Needle-Free Technology
Speedinject (search)'s core innovation lies in its ability to deliver medications without conventional needles. The system provides precise, painless, and hygienic drug administration while significantly reducing medical waste. Unlike traditional prefilled syringes that generate substantial hazardous waste, Speedinject produces minimal waste, limited to a recyclable glass cartridge.
The company is already developing a biodegradable cartridge variant, further enhancing the technology's environmental credentials. This focus on sustainability aligns with growing market demands for eco-friendly medical solutions.
Targeting High-Growth Markets
The technology is particularly well-positioned for the rapidly expanding weight loss medication market. According to industry analyses, weight loss injections are projected to experience a compound annual growth rate (CAGR) exceeding 18% globally between 2023 and 2030.
Speedinject (search) offers significant advantages for patients with needle phobia or those requiring chronic injections. Its patient-friendly design could increase medication adherence while providing a sustainable alternative to conventional injection systems.
Strategic Market Entry
With patents now secured in both the European Union and United States, More Impact AG (search) plans to launch Speedinject (search) by the end of 2025. The US pharmaceutical market, valued at approximately $634 billion in 2024, is expected to grow to $884 billion over the next five years, representing the world's largest pharmaceutical market.
"The granting of the US patent means that Speedinject (search) can now be launched on the market at the end of 2025, not only in the EU, where the relevant patents have already been granted," the company stated in its announcement.
Company Background
More Impact AG (search) (ISIN: DE000A1PG979) operates as a listed high-tech medical hub specializing in developing and supporting innovative medical companies. The firm focuses on securing patents and commercializing product innovations to make cutting-edge medical technologies widely accessible.
The company's business model includes strategic acquisitions and divestitures of companies, divisions, or individual patents. Through Speedinject (search) and other innovations, More Impact aims to contribute to sustainable improvements in global healthcare delivery while capitalizing on emerging market opportunities.